Phizer Original Brand Sulfasalazine 500 Mg Tablet
Sulfasalazine is used for the management of mild to moderate ulcerative colitis in adults and children 2 years of age or older and also has been used in the management of Crohn's disease in adult and pediatric patients. In addition, sulfasalazine administered as delayed-release tablets is used for the management of rheumatoid arthritis in adults and for the management of polyarticular course juvenile rheumatoid arthritis in children 6-16 years of age.
Sulfasalazine is used for the management of mild to moderate ulcerative colitis in conjunction with usual supportive and dietary measures. Corticosteroids are more effective than sulfasalazine in treating acute attacks and concomitant administration of corticosteroid retention enemas may be required. Patients who do not respond to concomitant sulfasalazine and topical corticosteroid therapy or who have extensive intestinal involvement may require systemic corticosteroids. Sulfasalazine is more effective than corticosteroids in reducing the frequency and severity of relapses, and usually is used for maintenance therapy. The manufacturers state that sulfasalazine also may be used as an adjunct in the treatment of severe ulcerative colitis. Controlled studies supporting this indication are lacking, and other treatment such as parenteral corticosteroids or surgery generally is required.
Sulfasalazine has been used for the management of mildly to moderately active Crohn's disease, but its role in the management of this condition is not as well defined as in the symptomatic treatment of ulcerative colitis.
Sulfasalazine may be used as initial drug therapy in patients with mildly to moderately active disease, especially in those with ileocolonic or colonic involvement; the drug does not seem be effective in patients with small bowel disease. Many clinicians recommend that sulfasalazine be used in patients with left-sided disease, restricted to the colon. Limited data indicate that patients who have been previously treated with corticosteroids or have undergone surgical resection may fail to respond to sulfasalazine therapy, while those who have not received corticosteroids at initiation of sulfasalazine therapy or did not undergo surgery may respond substantially better to sulfasalazine than those receiving placebo. There also is some evidence that concomitant therapy with sulfasalazine and corticosteroids may not be more effective than either drug alone, but some subgroups of patients may have a better response to combined therapy (e.g., those with disease localized in the colon).
Sulfasalazine does not appear to be useful for maintenance therapy in Crohn's disease once a remission has been attained by drug therapy or following surgical resection. However, limited data indicate that sulfasalazine may be superior to placebo in delaying clinical flare-ups in patients with Crohn's disease involving the colon and/or rectum, although results have been conflicting.
For additional information on the management of Crohn's disease, .
Rheumatoid Arthritis in Adults
Sulfasalazine is used for the management of rheumatoid arthritis in adults whose symptoms progress despite an adequate regimen of nonsteroidal anti-inflammatory agents (NSAIAs) or those intolerant to an adequate trial of recommended dosages of one or more NSAIAs. Sulfasalazine is one of several disease-modifying antirheumatic drugs (DMARDs) that can be used when DMARD therapy is appropriate. (For further information on the treatment of rheumatoid arthritis, .) Usually used in conjunction with analgesic and/or NSAIA therapy, at least until the beneficial effects of sulfasalazine are apparent. Administration of sulfasalazine alone is not a complete treatment for rheumatoid arthritis, and the drug only should be used as one part of a comprehensive treatment program, including non-drug therapies such as rest and physical therapy. Unlike anti-inflammatory agents, sulfasalazine does not produce immediate response in patients with this condition.
Sulfasalazine has been used in combination with other DMARDs (e.g., azathioprine, gold compounds, hydroxychloroquine, methotrexate, penicillamine) and/or systemic corticosteroids. In patients with rheumatoid arthritis, sulfasalazine improves grip strength, decreases erythrocyte sedimentation rate, reduces joint tenderness, and decreases duration of early morning stiffness. Limited data indicate that sulfasalazine appears to be as effective as gold compounds, hydroxychloroquine, or penicillamine in the management of rheumatoid arthritis.
Sulfasalazine is used for the management of the signs and symptoms of polyarticular course juvenile rheumatoid arthritis in children who have not responded adequately to NSAIAs. Safety and efficacy of sulfasalazine for the management of polyarticular course juvenile rheumatoid arthritis in children 6-16 years of age is supported by evidence from adequate and well-controlled studies in adults. Extrapolation of data from adults with rheumatoid arthritis to children with polyarticular course juvenile rheumatoid arthritis is based on similarities in disease and response to therapy in these patient populations and published studies. Because of the high frequency of adverse effects in children receiving sulfasalazine for the management of systemic course juvenile rheumatoid arthritis, use of the drug in children with this type of arthritis is not recommended.(See Pediatric Precautions.)
Sulfasalazine has been used with some success in the treatment of granulomatous colitis and scleroderma, and was reportedly beneficial in the treatment of collagenous colitis in one patient.
サラゾピリン500mg100錠／Phizer Original Brand Sulfasalazine 500 Mg Tablet
- 品番: 330
- 在庫: 在庫あり